fatrovax rhd
fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - Ónæmislyf fyrir leporidae - kanínur - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.
locametz
novartis europharm limited - gozetotide - radionuclide imaging - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
hjartamagnýl magasýruþolin tafla 75 mg
teva b.v.* - acidum acetylsalicylicum - magasýruþolin tafla - 75 mg
dolorin junior endaþarmsstíll 125 mg
williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 125 mg
dolorin junior endaþarmsstíll 250 mg
williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 250 mg
dolorin junior mixtúra, lausn 24 mg/ml
williams & halls ehf. - paracetamolum inn - mixtúra, lausn - 24 mg/ml
metoprolol alvogen (metoprolin) tafla 100 mg
alvogen ehf. - metoprololum tartrat - tafla - 100 mg
metoprolol alvogen (metoprolin) tafla 50 mg
alvogen ehf. - metoprololum tartrat - tafla - 50 mg
pylclari
curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).